ArticleVaccines2026
In-Use Stability and Device Compatibility Define Clinically Actionable Handling Limits for a GMP-Produced Attenuated
Jagmohan Singh, Taranjot Johar, Vannessa Scully, Scott A Waldman, Babar Bashir, Adam E Snook
Abstract read
In one paragraphArticle in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Jagmohan SinghDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Taranjot JoharDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Vannessa ScullyInvestigational Drug Service, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Scott A WaldmanDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0001-6619-175X Babar BashirDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0002-6843-1179 Adam E SnookDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0001-9216-4560 Funding
Targeting visceral pain through intestinal neuropod cell GUCY2C signalingR01DK138834 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI MANUEL L COVARRUBIAS, Scott A. Waldman · 2023 to 2026
$3.4MNeuroprotection by the GUCY2C gut-brain axis in Parkinson's diseaseR21NS130388 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2023 to 2023
$429kNIDDK NIH HHS R01 DK138834NIH HHS 1P30CA056036-00NIH HHS 1R21CA267087-00NIH HHS 1R21CA286339-00NINDS NIH HHS R21 NS130388Robert J Kleberg Jr and Helen C Kleberg Foundation N/ATargeted Diagnostic and Therapeutics, Inc. N/AUnited States Department of Defense W81XWH-22-1-0207United States Department of Defense W81XWH-22-1-0208
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
cancer vaccineguanylyl cyclase C (GUCY2C)in-use stabilityListeria monocytogenes
Identifiers
PMID42188831
PMCPMC13211327
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390